Core Insights - BGM Group's stock opened up by 9.28% on August 7, reaching $8.95 per share, with a total market capitalization of $1.646 billion [1] - As of March 31, 2025, BGM Group reported total revenue of $14.3114 million, reflecting a year-on-year growth of 13.92%, while net profit attributable to shareholders was -$0.8612 million, a significant decrease of 307.79% year-on-year [1] Company Overview - BGM Group, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on the biopharmaceutical, bio-extraction, and healthcare sectors [1] - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium [1] - Tetracycline raw materials are used not only for producing human antibiotics but also support the global aquaculture and livestock industries, ensuring the safety of poultry and seafood [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, serving as a major anticoagulant [1] - Licorice preparations, such as compound licorice tablets, are used as cough remedies and supplied to retail pharmacies [1]
博美集团上涨9.28%，报8.95美元/股，总市值16.46亿美元